Abstract
Background and Aims: Treatment decisions with regimens containing direct acting antivirals (DAA) highly depend on accurate fibrosis staging. Fibroscan® has become a gold standard for non-invasive staging of fibrosis; however this method is not universally available. Thus, we compared the performance of Fibroscan® to the standardly available serologic tests AST to platelet ratio (APRI) and FIB-4.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
